In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics, with a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors related to Gain Therapeutics’ ongoing clinical developments and financial positioning. The company is advancing its Phase 1b clinical study for GT-02287, a promising allosteric small molecule targeting Parkinson’s disease. The trial has reached its initial enrollment target ahead of schedule, and the company is seeking to extend the dosing duration, which could provide valuable insights for future Phase 2 trials. The anticipated biomarker data release in late 2025 is crucial, as it may reveal the mechanism of action for GT-02287, potentially offering neuroprotective benefits.
Financially, Gain Therapeutics has bolstered its cash reserves through a recent stock and warrant offering, raising $7 million. This, combined with existing cash, is expected to support operations into early 2026, beyond the key biomarker data release. While the company reported a wider-than-expected net loss in 2Q25, the financial strategy appears sound, providing a runway for continued development efforts. These factors collectively underpin Selvaraju’s confidence in the stock’s potential, leading to the reiterated Buy rating and a 12-month price target of $8.
In another report released on August 13, Oppenheimer also maintained a Buy rating on the stock with a $8.00 price target.